High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (Q55460949)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24782454 AND SRC:MED&resulttype=core&format=json

17 March 2020

title

High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24782454 AND SRC:MED&resulttype=core&format=json

17 March 2020

author

Martin J van den Bent

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24782454 AND SRC:MED&resulttype=core&format=json

ESMO Guidelines Working Group

17 March 2020

6

object named as

ESMO Guidelines Working Group

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24782454 AND SRC:MED&resulttype=core&format=json

17 March 2020

author name string

R Stupp

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24782454 AND SRC:MED&resulttype=core&format=json

17 March 2020

M Brada

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24782454 AND SRC:MED&resulttype=core&format=json

17 March 2020

J-C Tonn

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24782454 AND SRC:MED&resulttype=core&format=json

17 March 2020

G Pentheroudakis

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24782454 AND SRC:MED&resulttype=core&format=json

17 March 2020

publication date

29 April 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24782454 AND SRC:MED&resulttype=core&format=json

17 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24782454 AND SRC:MED&resulttype=core&format=json

17 March 2020

volume

25 Suppl 3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24782454 AND SRC:MED&resulttype=core&format=json

17 March 2020

page(s)

iii93-101

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24782454 AND SRC:MED&resulttype=core&format=json

Current concepts and management of glioblastoma

17 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

Malignant gliomas in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

Estimates of cancer incidence and mortality in Europe in 2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

Panel review of anaplastic oligodendroglioma from European Organization For Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

IDH1 and IDH2 mutations in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

Confirmation of R132H mutation of isocitrate dehydrogenase 1 as an independent prognostic factor in anaplastic astrocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

MGMT promoter methylation in malignant gliomas: ready for personalized medicine?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

Epilepsy in brain tumor patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

Epilepsy meets cancer: when, why, and what to do about it?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

Thromboembolic disease in patients with high-grade glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

Chemoradiotherapy in malignant glioma: standard of care and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

The combination of carmustine wafers and temozolomide for the treatment of malignant gliomas. A comprehensive review of the rationale and clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without prior gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

Radiotherapy for glioblastoma in the elderly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

A randomized trial of bevacizumab for newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

Prognostic factors for survival in adult patients with cerebral low-grade glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

PET Imaging in Glioma: The Neuro-Oncologist's Expectations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

Molecular neuro-oncology in clinical practice: a new horizon

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDU050

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDU050

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24782454 AND SRC:MED&resulttype=core&format=json

17 March 2020

1 reference